Lytgobi Dosage
Generic name: FUTIBATINIB 4mg
Dosage form: tablet
Drug class: Multikinase inhibitors
Medically reviewed by Drugs.com. Last updated on Apr 23, 2024.
Patient Selection
Select patients for the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with LYTGOBI based on the presence of an FGFR2 gene fusion or rearrangement. An FDA-approved test for detection of FGFR2 gene fusions or other rearrangements in patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma for selecting patients for treatment with LYTGOBI is not available.
Recommended Dosage
The recommended dosage of LYTGOBI is 20 mg (five 4 mg tablets) taken orally once daily until disease progression or unacceptable toxicity occurs.
Take LYTGOBI with or without food at approximately the same time each day.
Swallow tablets whole. Do not crush, chew, split, or dissolve tablets.
If the patient misses a dose of LYTGOBI for more than 12 hours or if vomiting occurs, resume dosing with the next scheduled dose.
Dosage Modification for Adverse Reactions
The recommended dose reductions for adverse reactions are provided in Table 1.
Dose Reduction |
Recommended Dosage |
---|---|
|
|
First dose reduction | 16 mg (four 4 mg tablets) orally once daily |
Second dose reduction* | 12 mg (three 4 mg tablets) orally once daily |
Recommended dosage modifications for adverse reactions are provided in Table 2.
Adverse Reaction | Severity | LYTGOBI Dosage Modifications |
---|---|---|
a Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03). | ||
Retinal Pigment Epithelial Detachment (RPED) | Not applicable | Continue LYTGOBI at the current dose and continue periodic ophthalmic evaluation:
|
Hyperphosphatemia | Serum phosphate ≥5.5 - ≤7 mg/dL | Continue LYTGOBI at the current dose and initiate phosphate lowering therapy. Monitor serum phosphate weekly. |
Serum phosphate >7 - ≤10 mg/dL |
|
|
Serum phosphate >10 mg/dL |
|
|
Other Adverse Reactions | Grade 3a |
|
Grade 4a | Permanently discontinue LYTGOBI |
More about Lytgobi (futibatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Pemazyre
Pemazyre is used to treat certain types of bile duct cancer and myeloid/lymphoid neoplasms ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.